

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Allen Andrew R</u> (Last) (First) (Middle) <u>C/O ADAPTIMMUNE THERAPEUTICS PLC,</u> <u>60 JUBILEE AVENUE, MILTON PARK</u> (Street) <u>ABINGDON X0 OX14 4RX</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Adaptimmune Therapeutics PLC [ADAP]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>07/05/2023</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
	Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Purchase Ordinary Shares	\$0.89 ⁽¹⁾⁽²⁾⁽³⁾	07/05/2023		A		73,212		(4)	12/12/2028	Ordinary Shares	73,212	\$0	73,212	D	
Option to Purchase Ordinary Shares	\$1.78 ⁽¹⁾⁽²⁾⁽⁵⁾	07/05/2023		A		56,868		(4)	04/10/2029	Ordinary Shares	56,868	\$0	56,868	D	
Option to Purchase Ordinary Shares	\$1.78 ⁽¹⁾⁽²⁾⁽⁵⁾	07/05/2023		A		45,348		(6)	12/18/2029	Ordinary Shares	45,348	\$0	45,348	D	
Option to Purchase Ordinary Shares	\$3.51 ⁽¹⁾⁽²⁾⁽⁷⁾	07/05/2023		A		109,746		(8)	12/09/2030	Ordinary Shares	109,746	\$0	109,746	D	
Option to Purchase Ordinary Shares	\$0.57 ⁽¹⁾⁽²⁾⁽⁹⁾	07/05/2023		A		109,746		(10)	12/08/2031	Ordinary Shares	109,746	\$0	109,746	D	
Option to Purchase Ordinary Shares	\$0.11 ⁽¹⁾⁽²⁾⁽¹¹⁾	07/05/2023		A		152,376		(12)	12/14/2032	Ordinary Shares	152,376	\$0	152,376	D	

Explanation of Responses:

- Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, as amended by Amendment No. 1 to Agreement and Plan of Merger, dated as of April 5, 2023 (the "Merger Agreement"), by and among the Issuer, CM Merger Sub, Inc. ("Merger Sub") and TCR2 Therapeutics, Inc. ("TCRR"), among other things, Merger Sub was merged with and into TCRR (the "Merger") with TCRR surviving the Merger as a wholly-owned subsidiary of the Issuer. Immediately prior to the effective time of the Merger, all outstanding and unexercised options to acquire shares of TCRR common stock (each, a "TCRR Option") were assumed by the Issuer and substituted for an option to purchase ordinary shares of the Issuer (each such share, an "Ordinary Share") (each such option, an "Adjusted Option"), with an exercise price equal to (A) the exercise price of such TCRR Option divided by (B) the product of 1.5117 multiplied by six (such product, the "Ordinary Share Exchange Ratio").
- The number of Ordinary Shares subject to the Adjusted Option is equal to (i) the Ordinary Share Exchange Ratio multiplied by (ii) the total number of shares of TCRR common stock subject to such TCRR Option. Each Adjusted Option was granted to the Reporting Person on the date set out in Column 3.
- The exercise price was converted from GBP0.70, based on an exchange rate of U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Currently exercisable.
- The exercise price was converted from GBP1.40, based on an exchange rate of U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Currently exercisable as to 39,684 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 944 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2024.
- The exercise price was converted from GBP2.76, based on an exchange rate of U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Currently exercisable as to 68,586 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 2,286 Ordinary Shares on the first of each month from August 1, 2023 through December 1, 2024 and 2,298 Ordinary Shares on January 1, 2025.
- The exercise price was converted from GBP0.46, based on an exchange rate of U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Currently exercisable as to 48,006 Ordinary Shares and will be exercisable as to the remainder in monthly installments of 3,430 Ordinary Shares on the first of each month from August 1, 2023 through January 1, 2025.
- The exercise price was converted from GBP0.09, based on an exchange rate of U.S. 1.2734 to GBP1.00. The actual exercise price will be the pounds sterling amount.
- Will be exercisable as to 38,094 Ordinary Shares on December 15, 2023 and will be exercisable as to the remainder in monthly installments of 4,758 Ordinary Shares on the fifteenth of each month from January 15, 2024 through November 15, 2025 and 4,848 Ordinary Shares on December 15, 2025.

/s/ Andrew Allen**

07/05/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.